Anping Li
- Cancer Research top 1%
- Cancer-related molecular mechanisms research 9
- MicroRNA in disease regulation 7
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers 5
- Immunology top 2%
- Immune cells in cancer 4
- Molecular Biology top 2%
- RNA modifications and cancer 5
- Angiogenesis and VEGF in Cancer 3
-
- Renal cell carcinoma treatment 3
- Ferroptosis and cancer prognosis 3
- Cited by
- Cancer ResearchOncologyImmunology
- Journals
- Journal of Hematology & Oncology (10 papers)Oncotarget (4 papers)Nature Communications (2 papers)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Anping Li
53 papers receiving 4.9k citations
Hit Papers
Peers
Comparison fields: 5 of 120
- Cancer Research 1.2k
- Oncology 1.9k
- Immunology 1.2k
- Molecular Biology 2.7k
- Pulmonary and Respiratory Medicine 668
Countries citing papers authored by Anping Li
This map shows the geographic impact of Anping Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anping Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anping Li more than expected).
Fields of papers citing papers by Anping Li
This network shows the impact of papers produced by Anping Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anping Li. The network helps show where Anping Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Anping Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 11 | |
| 2 | 2023 | 17 | |
| 3 | 2022 | 38 | |
| 4 | 2021 | 41 | |
| 5 | 2021 | 96 | |
| 6 | 2020 | 25 | |
| 7 | 2020 | 29 | |
| 8 | 2020 | 168 | |
| 9 | Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatmentbreakdown → | 2019 | 465 |
| 10 | 2019 | 32 | |
| 11 | 2017 | 234 | |
| 12 | 2017 | 83 | |
| 13 | 2016 | 59 | |
| 14 | The CXCL8-CXCR1/2 pathways in cancerbreakdown → | 2016 | 478 |
| 15 | 2015 | 148 | |
| 16 | 2014 | 35 | |
| 17 | 2014 | 166 | |
| 18 | 2013 | 22 | |
| 19 | 2009 | 66 | |
| 20 | 2009 | 152 |
About Anping Li
Anping Li is a scholar working on Cancer Research, Molecular Biology, Oncology, Immunology and Pulmonary and Respiratory Medicine, having authored 54 papers that have together received 4.9k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (9 papers), MicroRNA in disease regulation (7 papers), Cancer Immunotherapy and Biomarkers (5 papers), RNA modifications and cancer (5 papers), Immune cells in cancer (4 papers), Renal cell carcinoma treatment (3 papers), Ferroptosis and cancer prognosis (3 papers) and Angiogenesis and VEGF in Cancer (3 papers). The work is most often cited by research in Cancer Research (1.2k citations), Oncology (1.9k citations), Immunology (1.2k citations), Molecular Biology (2.7k citations) and Pulmonary and Respiratory Medicine (668 citations). Anping Li has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Kongming Wu, Ming Yi, Shuang Qin, Qian Chu, Dechao Jiao, Shengnan Yu, Suxia Luo, Tengfei Li, Xinwei Han and Qihong Huang. Their work appears in journals such as Journal of Hematology & Oncology, Oncotarget, Nature Communications, Experimental Hematology and Oncology and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.